drugset / Trial / NCT07396818
Kamlanoflast In Amyotrophic Lateral Sclerosis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected.
Timeline
- Start
- 2026-02
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Kamlanoflast | Unknown | — | Oral |